Ann Liver Transplant.  2023 Nov;3(2):63-68. 10.52604/alt.23.0021.

Biological immunosuppressive agents used in liver transplantation

• Park CS
• Chung YK

• KMID: 2560924
• DOI: http://doi.org/10.52604/alt.23.0021

Abstract

Liver transplantation (LT) has become the preferred treatment for conditions like end-stage liver failure and hepatocellular carcinoma. With advancements in immunosuppressive therapies over time, there have been significant improvements in both graft and patient survival rates. However, the side effects of these immunosuppressive drugs now pose a major challenge to the quality of life and long-term outcomes post-transplantation. The key goal of personalized immunosuppression is to strike a fine balance between effective immunosuppression and minimizing side effects. Immunosuppressive agents are generally divided into two main categories: biological and pharmacological agents. Most treatment protocols combine multiple agents with varied mechanisms of action to lower the required dosages and reduce toxicity. The post-transplant immunosuppression process typically involves an intensive phase in the initial three months, when alloreactivity is heightened, followed by a maintenance phase that incorporates immunosuppression minimization strategies. This review was focused on the biologic agents employed in the treatment of LT recipients.

Keyword

Biological agent; Acute rejection; Immunosuppression; Monoclonal antibody; Polyclonal antibody

Reference

1. Van Thiel DH, Schade RR, Starzl TE, Iwatsuki S, Shaw BW Jr, Gavaler JS, et al. 1982; Liver transplantation in adults. Hepatology. 2:637–640. DOI: 10.1002/hep.1840020517. PMID: 6749636. PMCID: PMC2965467.

2. Rana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H, et al. 2019; No gains in long-term survival after liver transplantation over the past three decades. Ann Surg. 269:20–27. DOI: 10.1097/SLA.0000000000002650. PMID: 29303806.

3. Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M, et al. 2018; International Liver Transplantation Society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 102:727–743. Erratum in: Transplantation 2019;103:e37. DOI: 10.1097/TP.0000000000002147. PMID: 29485508.

4. Halloran PF. 2004; Immunosuppressive drugs for kidney transplantation. N Engl J Med. 351:2715–2729. DOI: 10.1056/NEJMra033540. PMID: 15616206.

5. Bush WW. 1999; Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression. AACN Clin Issues. 10:253–269. quiz 304-306. DOI: 10.1097/00044067-199905000-00011. PMID: 10578712.

6. Wiesner RH, Fung JJ. 2011; Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 17 Suppl 3:S1–S9. DOI: 10.1002/lt.22410. PMID: 21850697.

7. Turner AP, Knechtle SJ. 2013; Induction immunosuppression in liver transplantation: a review. Transpl Int. 26:673–683. DOI: 10.1111/tri.12100. PMID: 23651083.

8. Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. 2014; Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev. 2014:CD010253. DOI: 10.1002/14651858.CD010253.pub2.

9. Yadav DK, Hua YF, Bai X, Lou J, Que R, Gao S, et al. 2019; ABO-incompatible adult living donor liver transplantation in the era of rituximab: a systematic review and meta-analysis. Gastroenterol Res Pract. 2019:8589402. DOI: 10.1155/2019/8589402. PMID: 31285743. PMCID: PMC6594289.

10. Lee CF, Eldeen FZ, Chan KM, Wu TH, Soong RS, Wu TJ, et al. 2012; Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc. 44:529–531. DOI: 10.1016/j.transproceed.2012.01.051. PMID: 22410063.

11. Lee JG, Lee J, Lee JJ, Song SH, Ju MK, Choi GH, et al. 2016; Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation. Medicine (Baltimore). 95:e3711. Erratum. DOI: 10.1097/MD.0000000000003711. PMID: 27281070. PMCID: PMC4907648.

12. Fernandes ML, Lee YM, Sutedja D, Wai CT, Isacc J, Prabhakaran K, et al. 2005; Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc. 37:2179–2180. DOI: 10.1016/j.transproceed.2005.03.030. PMID: 15964372.

13. Choudhary NS, Saigal S, Bansal RK, Saraf N, Gautam D, Soin AS. 2017; Acute and chronic rejection after liver transplantation: what a clinician needs to know. J Clin Exp Hepatol. 7:358–366. DOI: 10.1016/j.jceh.2017.10.003. PMID: 29234201. PMCID: PMC5715482.

14. Ramirez CB, Doria C, Frank AM, Armenti ST, Marino IR. 2013; Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant. 27:463–471. DOI: 10.1111/ctr.12119. PMID: 23621629.

15. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. ReSpECT Study Group. 2009; Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 9:327–336. DOI: 10.1111/j.1600-6143.2008.02493.x. PMID: 19120077.

16. Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, et al. 2007; Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 13:1039–1044. DOI: 10.1002/lt.21185. PMID: 17600336.

17. Schmitt TM, Phillips M, Sawyer RG, Northup P, Hagspiel KD, Pruett TL, et al. 2010; Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci. 55:3224–3234. DOI: 10.1007/s10620-010-1149-x. PMID: 20238251.

18. Langrehr JM, Nüssler NC, Neumann U, Guckelberger O, Lohmann R, Radtke A, et al. 1997; A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation. 63:1772–1781. DOI: 10.1097/00007890-199706270-00012. PMID: 9210503.

19. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. 1999; A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 67:1011–1018. Erratum in: Transplantation 1999;67: 1386. DOI: 10.1097/00007890-199904150-00013. PMID: 10221486.

20. Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, et al. 2007; Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int. 20:447–452. DOI: 10.1111/j.1432-2277.2007.00463.x. PMID: 17343686.

21. Moini M, Schilsky ML, Tichy EM. 2015; Review on immunosuppression in liver transplantation. World J Hepatol. 7:1355–1368. DOI: 10.4254/wjh.v7.i10.1355. PMID: 26052381. PMCID: PMC4450199.

22. Dhesi S, Boland B, Colquhoun S. 2009; Alemtuzumab and liver transplantation: a review. Curr Opin Organ Transplant. 14:245–249. DOI: 10.1097/MOT.0b013e32832b45d0. PMID: 19417659.

23. Magliocca JF, Knechtle SJ. 2006; The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int. 19:705–714. DOI: 10.1111/j.1432-2277.2006.00343.x. PMID: 16918530.

24. Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, et al. 1993; OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation. 55:87–91. DOI: 10.1097/00007890-199301000-00017. PMID: 8420070.

25. Geissler EK, Schlitt HJ. 2009; Immunosuppression for liver transplantation. Gut. 58:452–463. DOI: 10.1136/gut.2008.163527. PMID: 19052024.

26. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. 2006; Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc. 38:3633–3635. Erratum in: Transplant Proc 2007;39:779. DOI: 10.1016/j.transproceed.2006.10.110. PMID: 17175352.

27. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. 2011; Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 24:640–650. DOI: 10.1111/j.1432-2277.2011.01250.x. PMID: 21429047.

28. Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, et al. 2004; Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10:728–733. DOI: 10.1002/lt.20144. PMID: 15162466.

29. Di Maira T, Little EC, Berenguer M. 2020; Immunosuppression in liver transplant. Best Pract Res Clin Gastroenterol. 46-47:101681. DOI: 10.1016/j.bpg.2020.101681. PMID: 33158467.

30. Perez CP, Patel N, Mardis CR, Meadows HB, Taber DJ, Pilch NA. 2018; Belatacept in solid organ transplant: review of current literature across transplant types. Transplantation. 102:1440–1452. DOI: 10.1097/TP.0000000000002291. PMID: 29787522.

31. Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, et al. 2020; Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int. 14:930–943. Erratum in: Hepatol Int 2021;15:831. DOI: 10.1007/s12072-020-10091-5. PMID: 33099753. PMCID: PMC7803715.

32. Wong TC, Lo CM, Fung JY. 2017; Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. Expert Opin Emerg Drugs. 22:123–136. DOI: 10.1080/14728214.2017.1330884. PMID: 28503959.

33. Choudhary NS, Saigal S, Shukla R, Kotecha H, Saraf N, Soin AS. 2013; Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol. 3:150–158. DOI: 10.1016/j.jceh.2013.04.005. PMID: 25755489. PMCID: PMC3940114.

34. Saigal S, Shah SR. 2012; Liver transplantation--economics in the less developed world. Indian J Gastroenterol. 31:13–14. DOI: 10.1007/s12664-011-0159-8. PMID: 22228318.

35. Panackel C, Mathew JF, Fawas NM, Jacob M. 2022; Immunosuppressive drugs in liver transplant: an insight. J Clin Exp Hepatol. 12:1557–1571. DOI: 10.1016/j.jceh.2022.06.007. PMID: 36340316. PMCID: PMC9630030.